We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Evotec Completes Acquisition of DeveloGen


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec Completes Acquisition of DeveloGen"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 
Evotec AG announced the Closing of the agreement to acquire DeveloGen as announced in detail on 14 July 2010.
 
Following the successful fulfilment of various Closing conditions, the sellers of 99.3% of the shares in DeveloGen AG has transferred their shares to Evotec AG. Evotec AG issues 6,750,014 new Evotec Shares from its authorized capital as part consideration for the transaction. Following the registration of these shares at the trade register, Evotec’s issued share capital will increase to €115,588,729.
 
The transaction adds two complementary alliances - one with Boehringer Ingelheim and one with Andromeda (Teva) - to Evotec's portfolio of core assets. In addition, it augments and complements Evotec's high-end drug discovery platform and capability with DeveloGen's target discovery, validation and in vivo/in vitro pharmacology expertise and adds core disease biology know-how in metabolic diseases and endocrine disorders.
Advertisement